GlassScriptPhysician profile
Chad S Caskey
NPI 1104855907
$4,019.55
in general payments reported to CMS, 2019-2025
12 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $433 · 2023: $786 · 2024: $1,234 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.67 |
| Education | $360.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,007.16 | 2021-2025 | Tremfya |
| Abbvie INC. | $790.19 | 2021-2025 | |
| Ucb, INC. | $513.38 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $200.56 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $118.22 | 2023-2025 | Blu-U, Odomzo |
| Genzyme Corporation | $97.12 | 2021-2025 | |
| Pfizer INC. | $88.51 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Lilly USA, LLC | $40.26 | 2021 | |
| Incyte Corporation | $34.98 | 2021 | |
| Leo Pharma INC. | $25.23 | 2022 | |
| Organogenesis INC. | $18.94 | 2025 | Novachor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Caskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.